Zobrazeno 1 - 10
of 18
pro vyhledávání: '"R García-Fumero"'
Autor:
R. García-Fumero, M. Piñero-González
Publikováno v:
Actas Urológicas Españolas (English Edition).
Autor:
R. García-Fumero, M. Piñero-González
Publikováno v:
Actas Urológicas Españolas.
Autor:
R García-Fumero, Miguel Ángel Calleja-Hernández, Cristina Fernández-López, José Expósito-Hernández, S Portillo-Haro
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Numerous randomised controlled trials (RCT) have been conducted over recent decades to identify the optimal therapeutic option for patients with advanced non-small cell lung cancer (NSCLC). However, only modest clinical bene
Autor:
R Claramunt García, C Alarcon-Payer, JM Puerta-Puerta, R García-Fumero, A. Jiménez-Morales, Mdm García-Valdés
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance In managing chronic lymphocytic leukaemia (CLL), it is recommended that patients with TP53 deletion/mutation (TP53mut), who have a poor prognosis, are treated with ibrutinib as frontline therapy. Because of severe infectious
Autor:
N Márquez Pete, M Rodriguez Goicochea, R García Fumero, S Guijarro Herrera, E Gonzalez Del Valle, S Cano Domínguez
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance Early antifungal therapy for invasive pulmonary aspergillosis has been associated with better survival outcomes in immunocompromised patients. Isavuconazole, as well as caspofungin and liposomal amphotericin B (LAmB), is a r
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J Cabeza-Barrera, María Nuñez-Nuñez, R García Fumero, S Guijarro-Herrera, I Casas-Hidalgo, A Jiménez-Morales, L Martínez-Dueñas
Publikováno v:
Eur J Hosp Pharm
BACKGROUND: Mid-year supply problems of piperacillin/tazobactam (PT) led the Spanish Agency for Medicines and Health Products (AEMPS) to define a proposal to manage the approaching situation. AEMPS proffered some guidelines depending on the type of i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3657d5b7122a235dcaffef7aa8a3b862
https://europepmc.org/articles/PMC7535596/
https://europepmc.org/articles/PMC7535596/
Autor:
S Guijarro-Herrera, J Pasquau, R García-Fumero, M Sanchez-Argaiz, A Jiménez-Morales, S Sadyrbaeva
Publikováno v:
Eur J Hosp Pharm
Background The emergence of highly-resistant gram-negative bacteria, in particular acinetobacter baumanii pseudomonas aeruginosa, and carbapenem-resistant klebsiella species has been associated with high rates of morbidity and mortality. Therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d670d7fc2573a29da196a65096c601d
https://europepmc.org/articles/PMC7535293/
https://europepmc.org/articles/PMC7535293/
5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)
Autor:
C Collado García, S Cano Domínguez, S Guijarro Herrera, F Artime Rodríguez-Hermida, A Jiménez Morales, R García Fumero, L Gutiérrez Zúñiga, CM Valencia Soto
Publikováno v:
Eur J Hosp Pharm
Background Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR. Purpo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dc038c5eb5e45c3212b0f47f8338750
https://europepmc.org/articles/PMC7535737/
https://europepmc.org/articles/PMC7535737/
Publikováno v:
Eur J Hosp Pharm
Background Hidradenitis suppurativa (HS) is a chronic suppurative condition featuring inflammatory nodules, fistulas and scars. Its prevalence is estimated at 1% in Wwestern Europe. Adalimumab (Humira ® ) was approved in June 2015 as the first TNF b